Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...
Datroway is the second ADC brought to market by AZ and Daiichi Sankyo after Enhertu (trastuzumab deruxtecan), an HER2-targeting ADC that brought in sales of more than $2.7 billion in the first ...
Their original ADC, called Enhertu (trastuzumab deruxtecan), secured its seventh FDA indication on Jan. 27. The approval clears Enhertu for treating patients with HER2-low or HER2-ultralow metastatic ...
fDivision of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Via Mariano Semmola 52, Naples 80131, Italy gDepartment of Medicine, University of Udine, Via Palladio 8, ...
Compared to the combination of trastuzumab and pertuzumab, the VHH-Fc combos or their combination with trastuzumab demonstrated greater or comparable antitumor activity in both ligand-independent and ...
HEALTH workers in Sogeri, Central Province, now have a safe space to live while serving the rural community, thanks to a joint partnership that saw the completion of a three-bedroom house recently.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback